Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 40 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR New Study Finds Dogs Can Sniff Out Lung Cancer — And... April 10, 2019 England moves to a single-dose HPV vaccine June 21, 2023 Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity... January 16, 2023 Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy... June 13, 2019 Load more HOT NEWS Low-Dose Aspirin Could be an Alternative to Colectomy for Preventing Colorectal... Νέα διαγνωστική μέθοδος για τον καρκίνο, με τη συμβολή της Microsoft Helping Dogs—and Humans—with Cancer: NCI’s Comparative Oncology Studies Tratamiento agnóstico contra el cáncer: perspectiva de un experto
